Literature DB >> 25035298

The effects of carbamazepine on prefrontal activation in manic youth with bipolar disorder.

Marguerite Reid Schneider1, Christina C Klein2, Wade Weber2, Samantha M Bitter2, Kimberly B Elliott2, Stephen M Strakowski3, Caleb M Adler3, Melissa P DelBello4.   

Abstract

This preliminary study investigated the neurofunctional effects of carbamazepine-extended release (XR) treatment in 11 manic youth with bipolar disorder during performance of a sustained attention task, the Continuous Performance Task - Identical Pairs version (CPT-IP), during functional magnetic resonance imaging (fMRI). All patients underwent baseline fMRI, and 10 patients were scanned again at endpoint. Nine demographically matched healthy youth, who were scanned once, served as controls. Carbamazepine-XR treatment was associated with normalization of activation in right Brodmann area 10 (BA). These results suggest that carbamazepine-XR treatment may correct prefrontal dysfunction in adolescent mania.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adolescents; Functional magnetic resonance imaging (fMRI); Mania

Mesh:

Substances:

Year:  2014        PMID: 25035298      PMCID: PMC4279715          DOI: 10.1016/j.pscychresns.2014.04.011

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

1.  A group-test for assessing hand- and eye-dominance.

Authors:  H F CROVITZ; K ZENER
Journal:  Am J Psychol       Date:  1962-06

2.  Carbamazepine extended-release capsules: a retrospective review of its use in children and adolescents.

Authors:  Lawrence D Ginsberg
Journal:  Ann Clin Psychiatry       Date:  2006       Impact factor: 1.567

Review 3.  Power failure: why small sample size undermines the reliability of neuroscience.

Authors:  Katherine S Button; John P A Ioannidis; Claire Mokrysz; Brian A Nosek; Jonathan Flint; Emma S J Robinson; Marcus R Munafò
Journal:  Nat Rev Neurosci       Date:  2013-04-10       Impact factor: 34.870

4.  The effects of ziprasidone on prefrontal and amygdalar activation in manic youth with bipolar disorder.

Authors:  Marguerite Reid Schneider; Caleb M Adler; Rachel Whitsel; Wade Weber; Neil P Mills; Samantha M Bitter; James Eliassen; Stephen M Strakowski; Melissa P DelBello
Journal:  Isr J Psychiatry Relat Sci       Date:  2012       Impact factor: 0.481

5.  Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials.

Authors:  Christoph U Correll; Eva M Sheridan; Melissa P DelBello
Journal:  Bipolar Disord       Date:  2010-03       Impact factor: 6.744

6.  Fronto-limbic dysfunction in mania pre-treatment and persistent amygdala over-activity post-treatment in pediatric bipolar disorder.

Authors:  Alessandra M Passarotti; John A Sweeney; Mani N Pavuluri
Journal:  Psychopharmacology (Berl)       Date:  2011-03-10       Impact factor: 4.530

7.  A preliminary FMRI study of sustained attention in euthymic, unmedicated bipolar disorder.

Authors:  Stephen M Strakowski; Caleb M Adler; Scott K Holland; Neil Mills; Melissa P DelBello
Journal:  Neuropsychopharmacology       Date:  2004-09       Impact factor: 7.853

  7 in total
  7 in total

1.  fMRI brain activation changes following treatment of a first bipolar manic episode.

Authors:  Stephen M Strakowski; David E Fleck; Jeffrey Welge; James C Eliassen; Matthew Norris; Michelle Durling; Richard A Komoroski; Wen-Jang Chu; Wade Weber; Jonathan A Dudley; Thomas J Blom; Amanda Stover; Christina Klein; Jeffrey R Strawn; Melissa P DelBello; Jing-Huei Lee; Caleb M Adler
Journal:  Bipolar Disord       Date:  2016-09-19       Impact factor: 6.744

2.  Effects of short-term quetiapine and lithium therapy for acute manic or mixed episodes on the limbic system and emotion regulation circuitry in youth with bipolar disorder.

Authors:  Du Lei; Wenbin Li; Kun Qin; Yuan Ai; Maxwell J Tallman; L Rodrigo Patino; Jeffrey A Welge; Thomas J Blom; Christina C Klein; David E Fleck; Qiyong Gong; Caleb M Adler; Jeffrey R Strawn; John A Sweeney; Melissa P DelBello
Journal:  Neuropsychopharmacology       Date:  2022-10-13       Impact factor: 8.294

Review 3.  Effect of Pharmacological Interventions on the Fronto-Cingulo-Parietal Cognitive Control Network in Psychiatric Disorders: A Transdiagnostic Systematic Review of fMRI Studies.

Authors:  Thérèse van Amelsvoort; Dennis Hernaus
Journal:  Front Psychiatry       Date:  2016-05-18       Impact factor: 4.157

Review 4.  The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research.

Authors:  Benjamin I Goldstein; Boris Birmaher; Gabrielle A Carlson; Melissa P DelBello; Robert L Findling; Mary Fristad; Robert A Kowatch; David J Miklowitz; Fabiano G Nery; Guillermo Perez-Algorta; Anna Van Meter; Cristian P Zeni; Christoph U Correll; Hyo-Won Kim; Janet Wozniak; Kiki D Chang; Manon Hillegers; Eric A Youngstrom
Journal:  Bipolar Disord       Date:  2017-09-25       Impact factor: 6.744

5.  Age-specific effects of structural and functional connectivity in prefrontal-amygdala circuitry in women with bipolar disorder.

Authors:  Yanqing Tang; Yinzhu Ma; Xuemei Chen; Xuesheng Fan; Xiaowei Jiang; Yifang Zhou; Fei Wang; Shengnan Wei
Journal:  BMC Psychiatry       Date:  2018-06-05       Impact factor: 3.630

6.  When Thoughts Are in a Race: Area 10 and Bipolar Disorders.

Authors:  Shokouh Arjmand; Abdolreza Sabahi; Vahid Sheibani
Journal:  Psychiatry Investig       Date:  2019-10-16       Impact factor: 2.505

7.  Chronic Migraine Preventive Treatment by Prefrontal-Occipital Transcranial Direct Current Stimulation (tDCS): A Proof-of-Concept Study on the Effect of Psychiatric Comorbidities.

Authors:  Giulio Mastria; Alessandro Viganò; Alessandra Corrado; Valentina Mancini; Cristina Pirillo; Simone Badini; Barbara Petolicchio; Massimiliano Toscano; Marta Altieri; Roberto Delle Chiaie; Vittorio Di Piero
Journal:  Front Neurol       Date:  2021-05-13       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.